High beta biotech stocks receive new bullish ratings, Danny Naz notes

High beta biotech stocks receive new bullish ratings, Danny Naz notes
Biotech stocks get bullish analyst coverage

Danny Naz, industry influencer, reports that several high beta biotech stocks have received positive initial ratings from major firms.

Baird initiated coverage of LYEL with an Outperform rating, Rothschild started APGE with a Buy, and JPM issued an Overweight on ARWR.

Naz has previously tracked notable equity moves, citing Alcoa’s persistent climb above $64–$65 in recent trading due to strong flow and breakout strength in a recent article. He has also highlighted that detailed analysis of market drivers for 2026 is available through subscription to The Edge Lab service. These updates reflect his ongoing coverage of activity in high-momentum sectors.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.